Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

1. González-Barca, E.
2. Canales, M.
3. Cortés, M.
4. Vidal, M.J.
5. Salar, A.
6. Oriol, A.
7. Bargay, J.
8. Bello, J.L.
9. Sánchez, J.J.
10. Tomás, J.F.
11. Donato, E.
12. Ferrer, S.
13. Caballero, D.